New USC research has found that COVID-19 therapies cause few serious side effects, based on an evaluation of the full spectrum of evidence available from U.S. biomedical science. The review, published in Open Forum Infectious Diseases, incorporated 54 studies spanning inpatient and outpatient treatment, clinical trials and observational research. Only investigations comparing COVID-19 therapy with standard care, placebo or no treatment were examined, so that effects of the disease itself could reasonably be excluded. No significant association with serious adverse events was found for oral antivirals such as Paxlovid. Evusheld and other monoclonal antibodies that bind to the coronavirus’s spike protein, previously administered intravenously in hospital but no longer authorized by the FDA due to their lack of effectiveness against COVID-19 variants, were not associated with serious adverse events. Actemra, an IV monoclonal antibody that works somewhat differently and is also known by the generic name tocilizumab, was associated with infection and low white blood cell counts in some studies. Transfusions of convalescent plasma — a blood product taken from recovered COVID-19 patients — were linked with higher risk of internal bleeding, infection and blood clots. The serious adverse events identified align with current product labeling.

Researchers have developed a simple and cost-effective blood test capable of detecting Parkinson’s disease long before symptoms emerge, comparing the current state of diagnosing neurodegenerative diseases to the fight against cancer 50 years ago—when most cases were identified too late for effective treatment. The test quantifies specific RNA fragments in the blood, focusing on a repetitive RNA sequence that accumulates in Parkinson’s patients and a parallel decline in mitochondrial RNA, which deteriorates as the disease progresses. By measuring the ratio between these biomarkers, the test offers a highly accurate, non-invasive, rapid  and affordable diagnostic tool, providing hope for early interventions and treatments that could change the course of the disease.

SINGAPORE – 10 April 2025 – The A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB), a pioneering biomedical research institute under the Agency for Science, Technology and Research (A*STAR), marked its 40th anniversary today with a gala dinner graced by Guest-of-Honour Dr Tan See Leng, Minister for Manpower and Second Minister for Trade and Industry. The celebration underscored the institute’s four decades of scientific breakthroughs and its continuing role in shaping Singapore’s biomedical innovation landscape.

The American Association for Cancer Research (AACR)-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology will be presented to Crystal L. Mackall, MD, Fellow of the AACR Academy, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.